tbuckley/cabot-search huggingface dataset:
Abstract 298: Circular Rna Mmu_circ_008396 Attenuates Cardiac Remodeling After Myocardial Infarction in Mice
Authors: Venkata N Garikipati, Suresh K Verma, Zhongjian Cheng, May M Trungcao, Dongming Liang, Mohsin Khan, Cindy Benedict, Maria Cimini, Jessica Ibetti, Laurel Grisanti, Sarah M Schumacher, Erhe Gao, Joseph E Rabinowitz, Jeremy E Wilusz, David Goukassian, Steven Houser, Walter J Koch, Raj Kishore
Journal: Circulation Research (2017)

Recent studies highlighted that circular RNAs (circRNA) can play an important role in cardiac hypertrophy. However, the circRNAs in cardiac diseases is still limited. Using global circRNA expression profiling, we identified several circRNA transcripts that were differentially regulated post-MI in mice, including mmu_circ_008396 that is significantly down regulated. Cell fractionation experiments indicated that mmu_circ_008396 is highly enriched in endothelial cells in post-MI mice. Interestingly, we found a mmu_circ_008396 circRNA ortholog in humans, which was also significantly down regulated in ischemic cardiomyopathy patients. Further, overexpression of mmu_circ_008396 significantly enhanced tube formation and reduced apoptosis of human umbilical vein endothelial cells. For cardiac overexpression of mmu_circ_008396 circRNA, we created AAV9 viral particles and found that in vivo over expression attenuated LV dysfunction post-MI and enhanced neovascularization. Mechanistically, mmu_circ_008396 binds to its potential target miRNAs (mmu-miR-93-3p, mmu-miR-412-3p and mmu-miR-298-5p) and regulate hemeoxygenase-1/ VEGF signaling, thereby enhancing neovascularization and cardiac repair post-MI. These results indicate that mmu_circ_008396 circRNA might be a novel potential target to prevent cardiac remodeling and also highlight the significance of circRNAs in cardiovascular diseases.
Primate Studies Indicate That Subclinical and Acute Vitamin C Deficiency May Lead to Periodontal Disease
Journal: JAMA (1981)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
SANITATION IN JAPAN.
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer. A trial of oral penicillin V or placebo combined with pefloxacin. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer
Journal: JAMA (1994)

To determine the effect of oral penicillin V combined with a fluoroquinolone (pefloxacin) on the occurrence of fever and streptococcal and other gram-positive coccal bacteremic infections in granulocytopenic patients with cancer.Prospective randomized double-blinded placebo-controlled prophylactic trial.Inpatient setting in multiple cooperating cancer centers.Convenience sample with a total of 551 granulocytopenic patients, 95% of whom had leukemia or underwent bone marrow transplantation.Penicillin V (500 mg twice a day) vs placebo given in combination with oral pefloxacin (400 mg twice a day).Occurrence of fever and/or infection.Fever or infection (without fever) developed in 190 (71%) of 268 evaluable patients in the penicillin arm compared with 213 (80%) of 268 evaluable patients in the placebo arm (P = .03; 95% confidence interval [CI] for the difference, -16% to -1%). Bacteremia occurred in 58 (22%) of 268 placebo-treated patients and in 38 (14%) of 268 penicillin-treated patients (P = .03; 95% CI for the difference, -14% to -1%), primarily due to a reduction in streptococcal bacteremic episodes that occurred in 14 penicillin-treated patients (5%) and in 27 placebo-treated patients (10%) (P = .05; 95% CI for the difference, -9% to -0.3%). Gram-negative rod bacteremias occurred in only two patients (1%) and in five patients (2%), respectively. Logistic regression analysis also supported the treatment effect on the development of bacteremia.These results demonstrate that the addition of penicillin V to fluoroquinolone prophylaxis in granulocytopenic patients with cancer effectively reduces febrile episodes and the incidence of bacteremia, especially that due to streptococcal species.
BTS statement on malignant mesothelioma in the UK, 2007
Journal: Thorax (2007)

N Supportive and palliative care aims to provide relief from pain and other physical symptoms and to respond to emotional, psychological, social and spiritual needs.N Dyspnoea, cough and other symptoms should be managed according to palliative care guidelines.N Radical surgery should, for the foreseeable future, only be considered within randomised trials such as MARS and MesoVATS.N Peritoneal mesothelioma is related to asbestos exposure but is less common than pleural mesothelioma.ii2 BTS statement on malignant mesothelioma in the UK www.thoraxjnl.
Idiopathic Disease of the Myocardium
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Treatment of Anthrax.
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Syphilis
Authors: G. Marshall Crawford
Journal: New England Journal of Medicine (1945)

Congenital SyphilisA thorough study of congenital syphilis from the standpoint of fetal autopsy findings has been reported by Dippel.102 The perivascular tissues of the liver and lungs generally yielded the largest number of spirochetes. Sixteen (24 per cent) of 67 fetuses of syphilitic mothers showed spirochetes in the tissues. It is interesting that 2 of 9 fetuses of Wassermann-negative mothers yielded spirochetes. This is an excellent illustration of the fact that negative serologic findings in the mother are no assurance against congenital syphilis of the child. It bears out the wisdom of the long-held tenet that any woman who . . .
PEDIATRICS.
Journal: JAMA (1891)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Somnambulism
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prolonged zidovudine therapy: confounded by Pneumocystis carinii prophylaxis?
Authors: T. W. Odell
Journal: JAMA (1990)

<h3>To the Editor.—</h3> Zidovudine was shown to enhance survival and decrease the frequency of opportunistic infections in patients with acquired immunodeficiency syndrome and acquired immunodeficiency syndrome—related complex in the short-term 24-week phase II study published in 1987.<sup>1</sup>This benefit was obtained in the absence of chemoprophylaxis for opportunistic infections. During the subsequent uncontrolled continuation study,<sup>2</sup>all subjects received zidovudine. Chemoprophylaxis for the prevention of<i>Pneumocystis carinii</i>pneumonia (PCP) was left up to the discretion of each investigator. Fischl et al concluded that long-term zidovudine therapy continued to enhance survival and decrease the frequency of opportunistic infections. Some or all of the apparent benefit of zidovudine, however, may be due to prophylaxis for PCP. The number of patients who received PCP prophylaxis was not specified and comparisons were made against historical controls. Since the phase II trial in 1987, there has not been a single study, to our
Therapiefolgen
Authors: Peter Huppert, Ulrich Lörcher
Journal: Thorax (2003)

In diesem Kapitel werden Folgen medikamentöser, radioonkologischer und operativer Therapien auf das Atemwegssystem behandelt. Die Datenlage hierzu ist sehr begrenzt, die Literatur besteht aus Kasuistiken, kleineren Serien und experimenteller Grundlagenforschung.
Evaluation of the antitumor activity of gefitinib (ZD1839) in combination with celecoxib in patients with advanced esophageal cancer
Authors: W. L. Vervenne, J. M. Bollen, J. J. G. H. M. Bergman, C. Y. Nio, M. C. C. M. Hulshof, J. J. B. Van Lanschot, D. J. Richel
Journal: Journal of Clinical Oncology (2004)

4054 Background: The epidermal growth factor receptor (EGFR) is highly expressed in esophageal cancer and is associated with advanced disease, resistance to chemotherapy and radiotherapy, and poor prognosis. Furthermore, upregulation of cyclooxygenase 2 (COX2) has been observed in esophageal cancer, suggesting that COX2 may also play a role in esophageal carcinogenesis. In preclinical studies, COX2 inhibition decreased cell growth and increased apoptosis in esophageal cancer cells (Cancer Res 2000; 60: 5767–72). In this study, we examined the efficacy and tolerability of the combination of the orally active EGFR tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) with the COX2 inhibitor celecoxib (Celebrex) in patients with advanced esophageal cancer without previous exposure to chemotherapy. Methods: In this single-arm Phase II trial, patients received gefitinib (250 mg/day) and celecoxib (400 mg bid). Study objectives included evaluating tumor response, progression-free and overall survival, and tolerability. Results: To date, 15 patients have been recruited; 3 with squamous-cell carcinoma and 12 with adenocarcinoma. Fourteen patients were evaluable for response; 1 was not evaluable due to death from gastrointestinal bleeding as a result of tumor progression. At first evaluation after 2 months of treatment, 10 patients (71%) had disease progression while 3 (21%) had stable disease and are in follow-up with a mean time of 5.5 months. One patient was lost to follow-up and not evaluable. No radiologic remission was observed in any patient. All 15 patients were evaluable for tolerability. The most frequently occurring adverse event was acneiform skin rash, grade 1/2 in 6 patients (40%). No treatment-related grade 3/4 toxicities were seen. Conclusions: Combination treatment with gefitinib and celecoxib was generally well tolerated. Although 3 patients had disease stabilization, the lack of efficacy in this small study might preclude further clinical investigation of this combination. 'Iressa' is a trademark of the AstraZeneca group of companies. No significant financial relationships to disclose.
"Benign" monoclonal IgE gammopathy.
Authors: H Ludwig
Journal: BMJ (1981)

moon.Had we included admissions for self-injury and accidental poisoning, including smoke injury, the figures would have been 390 and 336.The mean number of selfpoisoning admissions, with standard deviation, on full moon days was 5 9 2 3 (range 2-10) but on new moon days only 5-1 2 6 (0-12).We made comparisons for each full moon and new moon pair, and found t= 1 8487, df= 61.If we merely ask whether there might be a significant difference among the pairs then p = 007, which does not reach standards for significance.However, the report from India specified a direction of difference and allowed a prediction, and if we consequently adopt a one-tailed test then p =0035.The likelihood that the higher rate of admissions for poisoning on full moon days than on new moon days in Edinburgh, as in Patna, could be a matter of chance alone would thus be only about 1 in 28.
Prognostic Value of Measurable Residual Disease after Venetoclax and Decitabine in Acute Myeloid Leukemia
Authors: Abhishek Maiti, Courtney D. DiNardo, Sa A Wang, Jeffrey L. Jorgensen, Tapan M. Kadia, Naval Daver, Nicholas J. Short, Musa Yilmaz, Naveen Pemmaraju, Gautam Borthakur, Prithviraj Bose, Ghayas C. Issa, Alessandra Ferrajoli, Elias Jabbour, Nitin Jain, Guillermo Garcia-Manero, Maro Ohanian, Koichi Takahashi, Guillermo Montalban-Bravo, Lucia Masarova, Jan A. Burger, Philip A. Thompson, Srdan Verstovsek, Koji Sasaki, Michael Andreeff, Caitlin R. Rausch, Kathryn Montalbano, Sherry A. Pierce, Hagop M. Kantarjian, Marina Konopleva, Farhad Ravandi
Journal: Blood (2020)
Evoked potential emerging as valuable medical tool
Journal: JAMA (1981)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Obliterative Bronchitis and Bronchiolitis with Bronchiectasis
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
NCI Proposes Privatization of the Journal
Journal: JNCI Journal of the National Cancer Institute (1995)

NCI Proposes Privatization of the Journal Get access JNCI: Journal of the National Cancer Institute, Volume 87, Issue 24, 20 December 1995, Page 1832, https://doi.org/10.1093/jnci/87.24.1832 Published: 20 December 1995
Long-term administration of isosorbide-5-mononitrate does not impair renal function in cirrhotic patients
Authors: F Salerno, G Borroni, E Lorenzano, D Solenghi, M Cazzaniga, F Bissoli, R Ceriani, R deFranchis
Journal: Hepatology (1996)

Isosorbide-5-mononitrate (Is-5-Mn), alone or combined with β- blockers, has been proposed for prophylaxis of variceal bleeding in cirrhosis. However, renal insufficiency, might be an important undesirable effect of this therapy, especially in patients with ascites. We assessed the changes in renal function induced in 26 cirrhotic patients by acute or chronic administration of Is-5-Mn. The acute administration of 20 mg of Is-5-Mn to 21 patients reduced mean blood pressure (83.4 ± 2.4 vs. 92.8 ± 3.4 mm Hg, P &lt; .001), urine volume (5.5 ± 0.8 vs. 8.7 ± 1.1 mL/min, P &lt; .05), urine sodium excretion (114 ± 19 vs. 244 ± 41 muEq/min, P &lt; .001), urine potassium excretion (41 ± 3.4 vs. 67 ± 8.5 muEq/min, P &lt; .001), and atrial natriuretic factor (74 ± 10 vs. 98 ± 12 pg/mL, P &lt; .005). The glomerular filtration rate was decreased in the 11 patients with ascites (57 ± 9 vs. 68 ± 12 mL/min, P &lt; .05), and plasma renin activity was increased in 4 ascitics. Twenty-one patients (16 from the acute study + 5 other patients) were given Is-5-Mn for 3 months at the dose of 80 mg/d. This did not affect blood pressure and renal function in patients without ascites, but reduced mean blood pressure (91.9 ± 3.4 vs. 89.6 ± 3 mm Hg, P &lt; .05), urine volume (5.8 ± 1.1 vs. 3.4 ± 0.9 mL/min, P &lt; .05), and urine sodium excretion (205 ± 38 vs. 99 ± 16 muEq/min, P &lt; .01) in those with ascites. There were no changes in glomerular filtration rate and renal plasma flow, while plasma renin activity increased in only 3 patients with ascites and 1 without. Systemic hemodynamics and renal function of cirrhotic patients, especially those with ascites, are affected adversely by acute administration of Is-5-Mn. Long-term administration of the drug is well tolerated by compensated patients and does not affect renal plasma flow nor glomerular filtration rate, but can induce hypotension and sodium retention in patients with ascites.